meta
|
evidence
oncology
Living systematic review and meta-analysis
breast cancer - HR positive
es-BC - HR positive - (neo)adjuvant (NA)
2
es-BC - HR-positive - 1st line (L1)
1
la/mBC - HR positive
2
la/mBC - HR positive - (neo)adjuvant (NA)
3
la/mBC - HR positive - NA - PIK3CA mutant
la/mBC - HR-positive - 1st line (L1)
13
la/mBC - HR positive - L1 - PIK3CA mutant
1
la/mBC - HR-positive - 2nd line (L2)
20
la/mBC - HR positive - L2 - all population
1
la/mBC - HR positive - L2 - PIK3CA mutant
1
AKT inhibitor
capivasertib based treatment
capivasertib plus paclitaxel
ipatasertib based treatment
ipatasertib plus paclitaxel
cyclin inhibitor
abemaciclib based treatment
abemaciclib plus aromatase inhibitor
abemaciclib plus endocrine therapy
palbociclib based treatment
palbociclib plus endocrine therapy
palbociclib plus letrozole
ribociclib based treatment
ribociclib plus letrozole
HER inhibitor
HER2 inhibitor
trastuzumab based treatment
trastuzumab plus endocrine therapy
TKI anti HER1/EGFR and HER2/neu
lapatinib based treatment
lapatinib plus fulvestrant
lapatinib plus letrozole
IGF-1R inhibitors
dalotuzumab plus ridaforolimus plus exemestane
VEGF(R) inhibitor
cediranib plus fulvestrant